Eduardo Coelho

Eduardo Coelho

Associate Professor

Federal University of Minas Gerais, Brazil

Tel: +553134094983






Network Investigator


Research Keywords: 

Leishmaniasis, vaccine, diagnosis, treatment, animal models, clinical trials, dogs, humans



I have published about 100 scientific articles, most of them as the main researcher, in all areas of leishmaniasis, including those on diagnosis, vaccine candidates and new treatments against canine and human cutaneous and visceral leishmaniasis. My main interest is to develop new studies in this area, which could be deepened and tested in the canine and human population.


Related Websites: 

UFMG website

UFMG postgraduate program in infection & tropical medicine website


Key Publications:

Ribeiro et al. 2018. A conserved Leishmania hypothetical protein evaluated for the serodiagnosisof canine and human visceral and tegumentary leishmaniasis, as well as a serological markerfor the posttreatment patient follow-up. doi: 10.1016/j.diagmicrobio.2018.05.026

Dias DS et al., 2018. Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis. doi: 10.1016/j.trsl.2018.05.001

Ribeiro et al. 2018. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans. doi: 10.1016/j.cellimm.2018.05.009

Oliveira MP et al. 2018. Small Myristoylated Protein-3, Identified as a Potential Virulence Factor in Leishmania amazonensis, Proves to be a Protective Antigen against Visceral Leishmaniasis. doi: 10.3390/ijms19010129

Ramos FF et al. 2017. Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection. doi: 10.1186/s13071-017-2576-8

Dias DS et al. 2018. Recombinant prohibitin protein of Leishmania infantum acts as a vaccine candidate and diagnostic marker against visceral leishmaniasis. doi: 10.1016/j.cellimm.2017.11.001

Dias DS et al. 2018. Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis. doi: 10.1017/S0031182017001731

Dias DS et al. 2017. Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis. doi: 10.1016/j.molimm.2017.09.017

Santos TTO et al. 2017. Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice. doi: 10.1016/j.actatropica.2017.03.008

Martins VT et al. 2017. A recombinant fusion protein displaying murine and human MHC class Iand II-specific epitopes protects against Leishmania amazonensis infection. doi: 10.1016/j.cellimm.2016.12.008